Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Given Consensus Rating of “Hold” by Brokerages

Posted by Geri Gentry on May 18th, 2026

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR – Get Free Report) has earned a consensus rating of “Hold” from the five brokerages that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $5.00.

A number of equities research analysts have recently issued reports on CTXR shares. HC Wainwright reissued a “buy” rating and issued a $4.00 price target on shares of Citius Pharmaceuticals in a research note on Monday. D. Boral Capital reissued a “buy” rating and issued a $6.00 price target on shares of Citius Pharmaceuticals in a research note on Wednesday, March 11th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Citius Pharmaceuticals in a research note on Friday, March 27th.

View Our Latest Report on CTXR

Citius Pharmaceuticals Trading Down 26.5%

CTXR stock traded down $0.19 during trading on Monday, reaching $0.52. 1,972,197 shares of the stock were exchanged, compared to its average volume of 650,802. The business has a 50 day moving average price of $0.79 and a 200-day moving average price of $0.91. Citius Pharmaceuticals has a 1 year low of $0.48 and a 1 year high of $2.48. The firm has a market capitalization of $11.53 million, a price-to-earnings ratio of -0.21 and a beta of 1.05.

Citius Pharmaceuticals (NASDAQ:CTXR – Get Free Report) last issued its earnings results on Friday, May 15th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of $0.39 by ($1.34). The business had revenue of $1.67 million for the quarter, compared to the consensus estimate of $18.79 million.

Institutional Investors Weigh In On Citius Pharmaceuticals

Several large investors have recently added to or reduced their stakes in CTXR. XTX Topco Ltd purchased a new position in Citius Pharmaceuticals in the second quarter worth approximately $32,000. NewEdge Advisors LLC acquired a new position in shares of Citius Pharmaceuticals in the 2nd quarter valued at $40,000. Asset Advisory Group Inc. purchased a new stake in Citius Pharmaceuticals in the 4th quarter valued at $46,000. Finally, Heights Capital Management Inc. acquired a new stake in Citius Pharmaceuticals during the 4th quarter worth $622,000. 16.88% of the stock is owned by hedge funds and other institutional investors.

Citius Pharmaceuticals Company Profile

(Get Free Report)

Citius Pharmaceuticals is a clinical‐stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital‐acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.

One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter‐related bloodstream infections without catheter removal.